Ketanov

Quick links to important sections

Ketanov

Selected form

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Ketanov

Ketanov: What Kind of Medicine Is It?

Property Description
Active Ingredient Ketorolac tromethamine
Pharmacological Class Non-steroidal Anti-inflammatory Drug (NSAID)
Origin Synthetic compound
Primary Forms Tablet (oral) and Solution for injection (parenteral)
General Purpose Short-term management of moderate to severe acute pain

Ketanov: Definition and Pharmacological Class

Ketanov is a specific brand name for the medicine containing the active ingredient Ketorolac tromethamine, which is classified as a potent Non-steroidal Anti-inflammatory Drug (NSAID). It possesses high analgesic potency within its category. The core substance, Ketorolac, is a synthetic compound derived from the pyrrolo-pyrrole group.

This medication is available by prescription (Rx status) and is specifically positioned for use in treating acute, severe discomfort. Unlike narcotic pain relievers, Ketorolac is a non-opioid analgesic, which means it provides strong pain relief through a mechanism distinct from narcotics and does not carry the associated dependence profile.

What is the Primary Purpose of Ketorolac?

The primary therapeutic goal of Ketorolac is the short-term management of moderate to severe acute pain. This medicine is designed specifically for high-intensity, short-duration episodes of discomfort.

The mechanism through which it provides this effect is achieved by acting as a cyclooxygenase (COX) inhibitor, thereby blocking the synthesis of prostaglandins. Prostaglandins are chemical messengers that trigger and sustain the sensations of pain. Ketorolac’s effectiveness in mitigating pain intensity makes it a non-narcotic option for acute post-operative pain protocols.

Available Forms: Tablets and Injection Solution

Ketanov is supplied as a single-ingredient product in two distinct dosage forms: tablets for oral formulation and a sterile solution for injection for parenteral formulation (intramuscular or intravenous administration). This dual-form availability allows for relief via injection in an initial acute care setting, followed by the oral tablets for continuation of the strictly limited-duration treatment regime.

Regulatory References

  1. Ketorolac - StatPearls (NIH)

What side effects are possible with Ketanov?

Ketanov (ketorolac tromethamine) carries specific risks and adverse reactions documented in government regulatory labeling.

Serious Warnings and Restrictions

The most significant risks involve the Gastrointestinal System and Cardiovascular System. Use is associated with an increased risk of serious gastrointestinal adverse events, including ulceration, bleeding, and perforation, which can be fatal. Likewise, an increased risk of serious cardiovascular thrombotic events (such as myocardial infarction and stroke) is documented, with this risk potentially increasing with the duration of use. Due to these risks, regulatory documents impose a strict maximum total combined duration of treatment (e.g., typically not to exceed five days).

Common and Occasional Adverse Reactions

Adverse reactions are classified by frequency and System-Organ Class. Commonly reported effects (occurring in 1% to 10% of patients) often involve the gastrointestinal tract and nervous system and include nausea, dyspepsia, abdominal pain, headache, and drowsiness. Other frequently reported reactions include edema and hypertension.

Population-Specific Safety Considerations

The drug is contraindicated in certain patient populations. This includes patients with active peptic ulcer disease, recent gastrointestinal bleeding or perforation, advanced renal impairment, and those at high risk of bleeding, particularly cerebrovascular bleeding. The drug is contraindicated in late pregnancy, labor, and delivery due to potential adverse effects on fetal circulation and uterine contractions. Elderly patients are recognized as being at greater risk for serious gastrointestinal and kidney-related adverse events.

Overdose and Emergency Response

Overdose and When to Seek Help

The regulatory documents define the required actions and potential manifestations in case of a Ketorolac tromethamine overdose.

Over-ingestion may present with observable symptoms generally consistent with an extension of known effects. Documented presentations include central nervous system effects such as lethargy and drowsiness, and gastrointestinal distress marked by nausea, vomiting, abdominal pain, and epigastric pain. Some cases of acute overdose may involve hyperventilation.

In rare scenarios, often associated with significant over-ingestion, severe outcomes are possible. These life-threatening complications listed in prescribing information include acute renal failure, respiratory depression, and coma. Gastrointestinal complications such as bleeding or erosive gastritis are also documented.

Emergency Actions Mandated by Regulators

For any suspected over-ingestion, the official guidance states that you must seek immediate medical attention or contact a Poison Control center without delay.

Management relies strictly on providing symptomatic and supportive treatment. Regulatory labels explicitly state that no specific antidote is known for Ketorolac overdose. Furthermore, procedures like hemodialysis or forced diuresis are documented as having limited efficacy due to the medicine's high protein-binding properties.

Therapeutic Uses of Ketanov

Ketanov: Main Uses and Benefits

Ketanov (Ketorolac tromethamine) is commonly used for the management of severe, acute symptomatic distress. It is applied for moderately severe acute pain where symptoms create noticeable physiological strain. The medication is used in situations involving certain distressing symptoms across several key clinical areas, including postoperative pain management, severe dental procedures, pain from acute musculoskeletal trauma, and intense menstrual cramps.

The primary benefit is that it provides support that helps ease the overall symptom burden in situations where additional symptomatic support is needed. It is particularly relevant in clinical settings that involve acute or unstable symptom patterns, and may help patients cope more steadily with symptom fluctuations.

“The analgesic is often applied during phases when symptoms become more noticeable after procedures, providing supportive relief for patients.”

By addressing symptoms related to physical discomfort and inflammatory states, it may assist with maintaining functional stability during phases of increased distress.


Quick Fact: Relief for Acute High-Grade Pain
Ketanov is primarily applied when symptoms create noticeable physiological strain and require short-term, supportive symptomatic assistance.

Regulatory References

  1. NIH DailyMed drug label

Eligibility and Restrictions for Use

Official Regulatory Eligibility for Ketanov

The use of Ketanov (ketorolac tromethamine) is strictly governed by population-specific eligibility rules outlined in regulatory labeling, primarily due to the drug’s potent effect on hemostasis and organ function. Use is generally allowed for adults (typically ge 17 years old) for short-term management only, not exceeding five days total.

Contraindicated Populations Restricted/Conditional Use
Gastrointestinal: Active peptic ulcers, GI bleeding, or history of perforation. Age ge 65 Years: Requires caution and often mandates reduced dosages due to increased risk.
Renal Function: Advanced renal impairment or risk of renal failure due to volume depletion. Mild/Moderate Organ Impairment: Requires special caution and dose adjustment (renal/hepatic).
Bleeding Risk: Suspected cerebrovascular bleeding, hemorrhagic diathesis, or high bleeding risk. Body Weight < 50 kg: Requires a reduced total daily dose.
Hypersensitivity: Known allergy to ketorolac or allergic reactions to aspirin/other NSAIDs. Concomitant Medication: Contraindicated with other NSAIDs, aspirin, probenecid, or pentoxifylline.
Peripartum/Surgical: Labor, delivery, breastfeeding, or peri-operative pain management in CABG surgery. Pediatric Patients: mathbfNot indicated for use; safety and efficacy are not established.

Eligibility is defined by official non-eligibility: the drug is mathbfcontraindicated in specific high-risk groups to prevent serious complications, and its use is mathbfnot established in the pediatric population.

What should I know about interactions with other medicines?

Ketanov Interactions with Other Medicines and Products

This section outlines the officially documented interaction patterns for Ketanov (ketorolac tromethamine) as defined in government regulatory sources. The profile is defined by combinations that are formally contraindicated, those that modify drug exposure, and those that result in harmful pharmacodynamic effects.

Formal Contraindicated Combinations

Co-administration is strictly prohibited with the following due to significant risk:

Interacting Substance/Class Regulatory Rationale
Aspirin or other NSAIDs Cumulative risk of serious NSAID-related adverse effects (e.g., gastrointestinal bleeding).
Probenecid Decreased clearance, leading to significantly increased Ketanov plasma levels and toxicity risk.
Anticoagulants (e.g., Warfarin) Substantial increase in the risk of serious, sometimes fatal, hemorrhage.
Lithium Salts Risk of increased serum lithium levels, potentially resulting in toxicity.
Pentoxifylline Increased risk of bleeding and hemorrhage.

Documented Pharmacodynamic Effects

Ketorolac can interact pharmacodynamically with cardiovascular medicines and other agents that affect bleeding:

  • Diuretics and ACE Inhibitors/ARBs: Ketanov may reduce the natriuretic (salt-excreting) and antihypertensive effects of these medicines, potentially increasing the risk of acute renal dysfunction, particularly in vulnerable patients.
  • Anti-platelet Agents (including SSRIs): Co-administration increases the risk of ulceration and bleeding due to additive anti-platelet and gastrointestinal effects.

Exposure and Administration Notes

  • Food: Oral administration after a high-fat meal officially results in a delayed time-to-peak concentration (T max). The overall extent of absorption is not affected by antacids.
  • Injectable Solution: The solution must not be mixed with certain substances (e.g., morphine sulfate) in a small volume due to physical incompatibility leading to precipitation.

Mechanism of Action

Dual Enzyme Blockade: The Core Mechanism

The primary biological action is the non-selective competitive inhibition of the Cyclooxygenase (COX) enzymes, specifically COX-1 and COX-2. The active component, the S-enantiomer, engages with the active site of these enzymes, preventing the conversion of arachidonic acid into chemical mediators known as prostaglandins ( PGE2) and thromboxanes. This molecular blockade of the arachidonic acid cascade results in an altered physiological output.


Dual-Site Action: Central and Peripheral Modulation

The mechanism involves action at both the peripheral site of stimulus and within the Central Nervous System (CNS), including the spinal cord. Reduced prostaglandin levels at the periphery decrease the sensitization threshold of pain-sensing nerve endings (nociceptors), while the drug's CNS activity reduces the central amplification of incoming signals. This dual-site pathway modulation contributes to the drug's total spectrum of physiological effects.


Mechanism Independence from Opioid Receptors

The entire physiological response is driven by the modulation of enzyme activity and prostanoid synthesis; the mechanism does not involve direct interaction with mu-opioid receptors. This mechanistic independence means the resulting physiological effects are confined to the eicosanoid pathway and do not involve opioid receptor signaling.

Dosage and Administration Information

Ketanov (ketorolac tromethamine) is administered via two primary routes: parenteral (intravenous or intramuscular injection) and the oral tablet. The medication’s administration is governed by a strict short-term use protocol, which mandates that the total combined duration of treatment, encompassing all forms, must not exceed five days.

Administration Routes and Scheduling

The protocol defines specific dose limits and intervals for standard adult patients (under 65 years of age and over 50 kg):

Route Standard Adult Dose Maximum Daily Dose
Parenteral (IV or IM) 30 mg every six hours 120 mg
Oral Tablet (Continuation) 10 mg every four to six hours 40 mg

The oral tablet is indicated exclusively as continuation therapy after initial treatment with the injection; it is not approved for use as the starting dose.

Special Population Rules and Procedural Constraints

A reduced maximum daily dose of 60 mg for parenteral use is officially required for patients 65 years of age or older, those weighing less than 50 kg, or those with documented renal impairment. All administrations must adhere to the principle of using the lowest effective dose for the shortest duration necessary.

Procedural instructions specify that the intravenous bolus must be administered slowly, over a period of no less than 15 seconds. For the oral tablet, administration should occur with a full glass of water, and the patient should remain upright for 15 to 30 minutes after intake.

Recent Clinical Evidence

Research Evidence Overview for Ketanov (Ketorolac)

This section summarizes the structure of clinical evidence for Ketanov, focusing on findings from official randomized controlled trials (RCTs) and systematic reviews, as reported by major health authorities. The research explored how this medicine was observed in specific, short-term settings for acute pain.


Evidence for Use in Postoperative Acute Pain Management

Research for Ketanov was primarily focused on exploring pain that arises immediately following various surgical procedures. These evaluations were studied for its use in adults undergoing procedures such as general, orthopedic, and dental surgeries, typically taking the form of Randomized Controlled Trials (RCTs).

In these studies, researchers examined patient-reported outcomes describing perceived discomfort. A significant focus of this research examined how studies observed patterns when the medicine was applied in studies examining patient-reported experiences alongside standard pain management; findings describe patterns observed in the studies related to the total amount of opioid pain medication required by the observed patient groups. The data show patterns related to how patients reported their experience during periods of heightened symptom activity, which contributes to the broader evidence landscape.


Study Duration and the Limitation of Short-Term Data

A defining feature of the available evidence is its strict focus on short-term use. Regulatory guidance requires that the total combined use (oral and injectable forms) was studied for a maximum duration of five days in adults. This limitation governed the design of nearly all major clinical trials.

Consequently, there is limited information for long-term outcomes, meaning the durability of the observed responses or how symptoms evolve past the five-day period are not well characterized by the existing studies. This research provides context for short-term changes, but long-term effects are not fully established because the trials were not designed to monitor outcomes beyond the immediate acute phase.


Evidence in Special Populations, Including Children

Research examined the use of Ketanov in children (age 2 years and older), typically in the postoperative setting. However, the evidence quality varies across studies for this younger group. Scientific reviews often rate the quality as low or very low, citing sample sizes were modest and that trial results were sometimes inconsistent. Subgroup findings are uncertain in children, and experts indicate that data for certain groups remain insufficient to fully validate findings.

Key Studies & References The Analgesic Efficacy of IV and IM Ketorolac: A Systematic Review (Focusing on Ceiling Effect)

Frequently Asked Questions (FAQ)

Common questions about Ketanov (FAQ)

Q: How quickly does Ketanov start working?

According to official product information, the analgesic effect typically begins soon after administration. For the injectable forms (IV or IM), the onset of pain relief is generally around 30 minutes, with the full maximum effect usually reached within one to two hours.


Q: How long does the effect of Ketanov typically last?

Studies indicate that the median duration of the analgesic effect of Ketanov typically lasts between four to six hours. The half-life of the active substance in adults is approximately 5 to 6 hours. This duration helps define the appropriate interval for repeat administration, as described in prescribing information.


Q: How does Ketanov compare to Tylenol or ibuprofen?

Ketanov (ketorolac) is classified as a potent Non-Steroidal Anti-inflammatory Drug (NSAID) and is generally reserved for the short-term management of moderate to severe acute pain. The medication is designated for pain that is moderate to severe and is generally used in settings like post-operative care.


Q: What happens if Ketanov is taken with alcohol?

Regulatory warnings indicate that consuming alcohol while taking this medication significantly increases the risk of serious gastrointestinal adverse events, including stomach bleeding. Alcohol and NSAIDs can both cause bleeding individually, and the combined use increases this risk.


Q: What are the signs of a serious reaction to Ketanov?

Documented signs of serious adverse events include chest pain, sudden weakness on one side of the body, or slurred speech (which may suggest cardiovascular events); or bloody/black, tarry stools, and vomiting material that looks like coffee grounds (which may suggest internal bleeding).


Q: Does Ketanov have different uses in different countries?

While specific dosage strengths or approved forms might vary slightly by region, the core approved use across major regulatory bodies remains consistent. Ketanov is primarily indicated globally for the short-term management of moderate to severe acute pain.


Q: Can Ketanov interact with herbal supplements?

Official information states that Ketanov affects the way blood clots, and therefore, combining it with any herbal supplements known to affect platelet function or increase bleeding risk may increase the potential for adverse effects.


Q: Is it normal to feel a burning sensation after taking the oral form of Ketanov?

Mild to moderate stomach pain and upset stomach are commonly reported side effects. While a severe burning sensation in the chest or stomach is listed as a less common symptom, official guidance indicates that persistent, severe, or worsening abdominal burning is a symptom that should be addressed by a healthcare professional.


Q: Why are people often told to take Ketanov with food?

Although taking Ketanov with a high-fat meal can slightly slow down the drug's absorption rate, regulatory information notes that taking the medication with food or a snack is a common practice used to reduce the chance of stomach upset and minimize the risk of gastrointestinal irritation.


Q: Can Ketanov cause mood changes?

While rare, official labeling has reported adverse psychiatric effects associated with ketorolac use. These may include feelings of anxiety, depression, or abnormal thinking. Official product information suggests that unusual changes in behavior or mood are symptoms to discuss with a healthcare professional.


Q: Does Ketanov have a risk of severe skin reactions?

The medication carries a risk of serious skin reactions, which can include exfoliation, blistering, and peeling. Official warnings state that the medication should be stopped at the first sign of a rash or other hypersensitivity reaction, and any new or worsening symptoms should be brought to the attention of a medical professional.


Q: Are there any long-term risks associated with using Ketanov?

The drug is approved only for short-term use, defined as a maximum of five days total. This strict limit is imposed because the risk of serious adverse events—specifically gastrointestinal bleeding and cardiovascular thrombotic events—is higher with longer duration of use.


Q: Can people with liver problems use Ketanov?

Official information states that Ketanov is contraindicated, or strictly prohibited, in patients with severe liver impairment or active liver disease. The use of the medication in cases of mild to moderate liver dysfunction requires special consideration, and official prescribing information highlights the need for liver function to be monitored in these patients.


Q: How is Ketanov different from other NSAIDs?

Ketanov is pharmacologically classified as a potent Non-Steroidal Anti-inflammatory Drug (NSAID) and is specifically used for the short-term management of moderately severe pain. Its core mechanism of action is similar to other NSAIDs, and its potent effect requires a strict limit on the total duration of use, which is tied to the documented risk of serious gastrointestinal events.


Q: What distinguishes Ketanov from generic versions?

Ketanov is a brand name for the active ingredient ketorolac tromethamine. While the active ingredient, strength, and core clinical effect must be identical between the brand and generic products, the generic versions may differ in certain inactive ingredients, color, or shape.


Q: What types of allergic reactions are possible with Ketanov?

Hypersensitivity reactions are possible and can range in severity. Documented reactions include skin issues such as rash and hives, swelling of the face, tongue, or throat, and severe anaphylactic-like reactions, which may include trouble breathing or bronchospasm.

How should Ketanov be stored and disposed of?

Storage Requirements

Ketanov (ketorolac tromethamine) must be stored at Controlled Room Temperature, which is 20^circ to 25 C (68^circ to 77 F). The medication must be protected from light and excessive humidity to maintain product stability. Tablets should be stored in a tight, light-resistant container that is equipped with a child-resistant closure for safety. All medications must be kept out of the sight and reach of children.

Disposal Instructions

Disposal of unused or expired Ketanov must be done according to local regulations for pharmaceutical waste. The medication is not on the list of drugs recommended for flushing down the toilet. If a drug take-back program is unavailable, official guidance requires mixing the product with an unappealing substance, such as dirt or used coffee grounds, before sealing and discarding it in the household trash.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Ketanov found in:

A-Z Index: